Biolase, INC 8-K filings

BIOLASE, Inc. has been moved to the OTC Pink Market after failing to meet the continued eligibility standards for the OTCQB market.

Biolase, a dental laser company, has filed for Chapter 11 bankruptcy and entered into an asset purchase agreement with Sonendo, a dental technology company, for a potential sale of its assets.

BIOLASE, Inc. has entered into a forbearance agreement with its lenders to avoid immediate loan acceleration and to facilitate a sale of assets through a Chapter 11 bankruptcy filing.

Biolase Inc. received a default notice for missing a payment under its credit agreement, but has been granted an extension until August 30, 2024.

BIOLASE reported its second quarter 2024 financial results, highlighting a 40% gross margin and strong consumable revenue despite overall revenue challenges.

BIOLASE, Inc. issued 3,190,476 shares of common stock in exchange for preferred stock and warrants on July 16, 2024.

BIOLASE, Inc. has been notified by Nasdaq that its common stock will be delisted and trading will be suspended on June 20, 2024, due to non-compliance with listing rules.

BIOLASE, Inc. has received a notification from Nasdaq regarding its failure to meet the minimum stockholders' equity requirement, adding to existing delisting concerns.

BIOLASE reported its first quarter 2024 financial results, showing increased adoption of dental lasers and improved cost structure, while reiterating its full-year revenue growth and profitability guidance.

BIOLASE, Inc. held its 2024 Annual Meeting of Stockholders on May 2, 2024, where stockholders voted on ten proposals, including the election of directors, executive compensation, and a potential reverse stock split.

BIOLASE, Inc. has received a notice from Nasdaq regarding potential delisting due to its stock price falling below the required minimum bid price of $1.00 for 30 consecutive business days.

BIOLASE achieved a 1% revenue increase in 2023 despite industry challenges and anticipates stronger growth and positive adjusted EBITDA in 2024.

BIOLASE, Inc. has received a notice from Nasdaq that its stock price has fallen below the minimum $1.00 per share requirement, potentially leading to delisting.

BIOLASE, Inc. disclosed that it had 30,796,754 shares of common stock outstanding as of February 26, 2024.

BIOLASE, Inc. disclosed that as of February 19, 2024, it had 23,334,852 shares of common stock issued and outstanding.

BIOLASE, Inc. successfully closed a $7 million public offering, issuing units consisting of common stock (or pre-funded warrants), Class A warrants, and Class B warrants.

BIOLASE, Inc. anticipates a net operating loss between $17 million and $20 million for 2023, marking a 21% to 33% improvement over the previous year.

BIOLASE announced preliminary unaudited revenue growth for 2023 and provided an optimistic outlook for 2024, including revenue growth and improved profitability.